Newman Lori, Rowley Jane, Vander Hoorn Stephen, Wijesooriya Nalinka Saman, Unemo Magnus, Low Nicola, Stevens Gretchen, Gottlieb Sami, Kiarie James, Temmerman Marleen
Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Consultant to Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
PLoS One. 2015 Dec 8;10(12):e0143304. doi: 10.1371/journal.pone.0143304. eCollection 2015.
Quantifying sexually transmitted infection (STI) prevalence and incidence is important for planning interventions and advocating for resources. The World Health Organization (WHO) periodically estimates global and regional prevalence and incidence of four curable STIs: chlamydia, gonorrhoea, trichomoniasis and syphilis.
WHO's 2012 estimates were based upon literature reviews of prevalence data from 2005 through 2012 among general populations for genitourinary infection with chlamydia, gonorrhoea, and trichomoniasis, and nationally reported data on syphilis seroprevalence among antenatal care attendees. Data were standardized for laboratory test type, geography, age, and high risk subpopulations, and combined using a Bayesian meta-analytic approach. Regional incidence estimates were generated from prevalence estimates by adjusting for average duration of infection. In 2012, among women aged 15-49 years, the estimated global prevalence of chlamydia was 4.2% (95% uncertainty interval (UI): 3.7-4.7%), gonorrhoea 0.8% (0.6-1.0%), trichomoniasis 5.0% (4.0-6.4%), and syphilis 0.5% (0.4-0.6%); among men, estimated chlamydia prevalence was 2.7% (2.0-3.6%), gonorrhoea 0.6% (0.4-0.9%), trichomoniasis 0.6% (0.4-0.8%), and syphilis 0.48% (0.3-0.7%). These figures correspond to an estimated 131 million new cases of chlamydia (100-166 million), 78 million of gonorrhoea (53-110 million), 143 million of trichomoniasis (98-202 million), and 6 million of syphilis (4-8 million). Prevalence and incidence estimates varied by region and sex.
Estimates of the global prevalence and incidence of chlamydia, gonorrhoea, trichomoniasis, and syphilis in adult women and men remain high, with nearly one million new infections with curable STI each day. The estimates highlight the urgent need for the public health community to ensure that well-recognized effective interventions for STI prevention, screening, diagnosis, and treatment are made more widely available. Improved estimation methods are needed to allow use of more varied data and generation of estimates at the national level.
对性传播感染(STI)的流行率和发病率进行量化,对于规划干预措施和争取资源至关重要。世界卫生组织(WHO)定期估算四种可治愈性传播感染的全球及区域流行率和发病率,这四种感染分别为:衣原体感染、淋病、滴虫病和梅毒。
WHO 2012年的估算基于对2005年至2012年普通人群中衣原体、淋病和滴虫病泌尿生殖系统感染患病率数据的文献综述,以及各国报告的产前检查人群梅毒血清阳性率数据。数据针对实验室检测类型、地理位置、年龄和高危亚人群进行了标准化处理,并采用贝叶斯荟萃分析方法进行合并。通过对感染平均持续时间进行调整,从患病率估算值得出区域发病率估算值。2012年,在15 - 49岁女性中,衣原体感染的全球估算患病率为4.2%(95%不确定区间(UI):3.7 - 4.7%),淋病为0.8%(0.6 - 1.0%),滴虫病为5.0%(4.0 - 6.4%),梅毒为0.5%(0.4 - 0.6%);在男性中,衣原体感染的估算患病率为2.7%(2.0 - 3.6%),淋病为0.6%(0.4 - 0.9%),滴虫病为0.6%(0.4 - 0.8%),梅毒为0.48%(0.3 - 0.7%)。这些数字对应约1.31亿例衣原体新发病例(1.00 - 1.66亿)、7800万例淋病(5300 - 1.10亿)、1.43亿例滴虫病(9800 - 2.02亿)和600万例梅毒(400 - 800万)。患病率和发病率估算值因地区和性别而异。
成年女性和男性中衣原体、淋病、滴虫病和梅毒的全球流行率和发病率估算值仍然很高,每天有近100万例可治愈性传播感染新病例。这些估算结果凸显了公共卫生界迫切需要确保更广泛地提供公认有效的性传播感染预防、筛查、诊断和治疗干预措施。需要改进估算方法,以便能够使用更多样化的数据并在国家层面生成估算值。